Anthrax immune globulin intravenous (human) (AIGIV) was approved for patient 1, but was not given because she had improved by the time of its arrival.
What does AIG stand for?
AIG stands for Anthrax Immune Globulin (antitoxin)
This definition appears very rarely and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of AIG
We have 171 other meanings of AIG in our Acronym Attic
- Advanced Instrumentation Group
- Advertising Information Group (Brussels, Belgium)
- Aging Interest Group (various universities)
- Ain't I Great
- Air Intelligence Group
- Airbus Industries Group
- Alternative Investments Group
- American International Group, Inc
- Amplifier Interface Group
- Answers in Genesis (religious group in defense of Scripture)
- Antitrust and Indemnity Group
- Apollo Invest Group
- Apprenticeship Incentive Grant (Canada)
- Aquilini Investment Group (Canada)
- Arbeitsgemeinschaft für Informationsverarbeitung in Gynäkologie Und Geburtshilfe
- Architecture Integration Group
- Army Initiatives Group
- Artificial Intelligence Group
- Asian Indoor Games (est. 2005)
- Asociación de Industriales de Guatemala (Association of Industrialists of Guatemala 1929-34)
Samples in periodicals archive:
Contract Awarded to potentially provide its Anthrax Immune Globulin Intravenous (AIGIV).
government, including development contracts related to the development of the company's anthrax immune globulin and anthrax monoclonal antibody product candidates, and BioThrax[R] product extensions.
8 million to support the development of the company's anthrax immune globulin (AIG) therapeutic product.
Emergent's portfolio of biodefense products to protect against biological attacks include: BioThrax(R), an FDA approved anthrax vaccine, which is being sold to the United States government, among other customers, anthrax immune globulin for treatment of inhalational anthrax, next generation anthrax vaccines, and recombinant botulinum and botulinum toxoid vaccines.
Commenced what we expect will be the only clinical trial of the company's polyclonal anthrax immune globulin (AIG) candidate for treating anthrax disease;
Department of Health and Human Services ("HHS") has exercised its option to purchase 10,000 doses of anthrax immune globulin ("AIG") under a modification to an earlier development and supply contract.
government, including development contracts related to the development of the company's anthrax immune globulin and anthrax monoclonal antibody product candidates, and BioThrax([R]) product extensions.